Skip to main content
SpringerLink
Log in

The Spectrum of NAFLD: From the Organ to the System

  • Chapter
  • First Online:
NAFLD and NASH

  • 739 Accesses

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a clinical-pathological condition that encompasses a wide range of liver damage not caused by chronic alcohol consumption, including steatosis, non-alcoholic steatohepatitis (NASH) and cirrhosis, in the absence of other etiologies. It is associated with metabolic risk factors such as obesity, dyslipidemia, and diabetes mellitus. The prevalence of NAFLD has increased considerably over the last years due to the current lifestyle (unhealthy diet and sedentarism). Despite NAFLD is considered the hepatic manifestation of the metabolic syndrome, there is an increasing number of studies that support a bidirectional model, in which NAFLD plays a crucial role in the development of metabolic disturbances. Also, there is strong evidence that supports the multisystemic affectation of NAFLD, including cardiovascular, bone and kidney disease, and promoting hepatic and extrahepatic malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of nonalcoholic steatohepatitis. Cell Mol Life Sci. 2016;73(10):1969–87.

    Article  CAS  PubMed  Google Scholar 

  2. Higuera-de la Tijera F, Servín-Caamaño AI. Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets. World J Hepatol. 2015;7(10):1297–301.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ampuero J, Aller R, Gallego-Durán R, Banales JM, Crespo J, García-Monzón C, et al. The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity. Aliment Pharmacol Ther. 2018;48(11–12):1260–70.

    Article  CAS  PubMed  Google Scholar 

  4. Barrera F, George J. The role of diet and nutritional intervention for the management of patients with NAFLD. Clin Liver Dis. 2014;18(1):91–112.

    Article  PubMed  Google Scholar 

  5. Gerber L, Otgonsuren M, Mishra A, Escheik C, Birerdinc A, Stepanova M, et al. Non-alcoholic fatty liver disease (NAFLD) is associated with low level of physical activity: a population-based study. Aliment Pharmacol Ther. 2012;36(8):772–81.

    Article  CAS  PubMed  Google Scholar 

  6. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012;142(7):1592–609.

    Article  PubMed  Google Scholar 

  7. McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015;62(5):1148–55.

    Article  PubMed  Google Scholar 

  8. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138–53.

    Article  PubMed  Google Scholar 

  9. Li AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2019;15(2):75–85.

    Google Scholar 

  10. Wong VW-S, Adams LA, de Lédinghen V, Wong GL-H, Sookoian S. Noninvasive biomarkers in NAFLD and NASH—current progress and future promise. Nat Rev Gastroenterol Hepatol. 2018;15(8):461–78.

    Article  CAS  PubMed  Google Scholar 

  11. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–57.

    Article  PubMed  Google Scholar 

  12. Wong VW-S, Chan W-K, Chitturi S, Chawla Y, Dan YY, Duseja A, et al. Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment. J Gastroenterol Hepatol. 2018;33(1):70–85.

    Article  PubMed  Google Scholar 

  13. Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547–54.

    Article  CAS  PubMed  Google Scholar 

  14. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, Younossi ZM, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547–55.

    Article  PubMed  Google Scholar 

  15. Sanchez-Torrijos Y, Ampuero J, Romero-Gómez M. Cardiovascular assessment in liver transplant for non-alcoholic steatohepatitis patients: what we do, what we should do. World J Hepatol. 2017;9(15):697.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ampuero J, Gallego-Durán R, Romero-Gómez M. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. Rev Esp Enferm Dig. 2015;107(1):10–6.

    PubMed  Google Scholar 

  17. VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology. 2015;62(3):773–83.

    Article  CAS  PubMed  Google Scholar 

  18. Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, et al. Progression of carotid vascular damage and cardiovascular events in non-alcoholic fatty liver disease patients compared to the general population during 10 years of follow-up. Atherosclerosis. 2016;246:208–13.

    Article  CAS  PubMed  Google Scholar 

  19. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6(1):33386.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–402.

    Article  Google Scholar 

  21. Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci. 2016;17(4):1–15.

    Article  CAS  Google Scholar 

  22. Musso G, Cassader M, Cohney S, Pinach S, Saba F, Gambino R. Emerging liver-kidney interactions in nonalcoholic fatty liver disease. Trends Mol Med. 2015;21(10):645–62.

    Article  CAS  PubMed  Google Scholar 

  23. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin J Am Soc Nephrol. 2010;5(12):2166–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680.

    Article  PubMed  PubMed Central  Google Scholar 

  25. VanWagner LB, Rinella ME. Extrahepatic manifestations of nonalcoholic fatty liver disease. Curr Hepatol Rep. 2016;15(2):75–85.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Yu J, Shen J, Sun TT, Zhang X, Wong N. Obesity, insulin resistance, NASH and hepatocellular carcinoma. Semin Cancer Biol. 2013;23(6 Pt B):483–91.

    Article  CAS  PubMed  Google Scholar 

  27. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007;97(7):1005–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Wainwright P, Scorletti E, Byrne CD. Type 2 diabetes and hepatocellular carcinoma: risk factors and pathogenesis. Curr Diab Rep. 2017;17(4):20.

    Article  CAS  PubMed  Google Scholar 

  29. Hassan MM, Abdel-Wahab R, Kaseb A, Shalaby A, Phan AT, El-Serag HB, et al. Obesity early in adulthood increases risk but does not affect outcomes of hepatocellular carcinoma. Gastroenterology. 2015;149(1):119–29.

    Article  PubMed  Google Scholar 

  30. Adami HO, Chow WH, Nyrén O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88(20):1472–7.

    Article  CAS  PubMed  Google Scholar 

  31. Lai M-S, Hsieh M-S, Chiu Y-H, Chen TH-H. Type 2 diabetes and hepatocellular carcinoma: a cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006;43(6):1295–302.

    Article  PubMed  Google Scholar 

  32. Tanaka K, Tsuji I, Tamakoshi A, Matsuo K, Wakai K, Nagata C, et al. Diabetes mellitus and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. Jpn J Clin Oncol. 2014;44(10):986–99.

    Article  PubMed  Google Scholar 

  33. Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62(6):1723–30.

    Article  CAS  PubMed  Google Scholar 

  34. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59(6):2188–95.

    Article  PubMed  Google Scholar 

  35. Mittal S, El-Serag HB, Sada YH, Kanwal F, Duan Z, Temple S, et al. Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2016;14(1):124–131.e1.

    Article  CAS  PubMed  Google Scholar 

  36. Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: a multicenter prospective study. Hepatology. 2016;63(3):827–38.

    Article  PubMed  Google Scholar 

  37. Aller R, Fernández-Rodríguez C, lo Iacono O, Bañares R, Abad J, Carrión JA, et al. Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. Gastroenterol Hepatol. 2018;41(5):328–49.

    Article  PubMed  Google Scholar 

  38. Bergström A, Pisani P, Tenet V, Wolk A, Adami HO. Overweight as an avoidable cause of cancer in Europe. Int J Cancer. 2001;91(3):421–30.

    Article  PubMed  Google Scholar 

  39. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348(17):1625–38.

    Article  PubMed  Google Scholar 

  40. Kim G-A, Lee HC, Choe J, Kim M-J, Lee MJ, Chang H-S, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol. 2018;68(1):140–6.

    Article  Google Scholar 

  41. Parizadeh SM, Parizadeh SA, Alizade-Noghani M, Jafarzadeh-Esfehani R, Ghandehari M, Mottaghi-Moghaddam A, et al. Association between non-alcoholic fatty liver disease and colorectal cancer. Expert Rev Gastroenterol Hepatol. 2019;13(7):633–41. https://doi.org/10.1080/17474124.2019.1617696.

    Article  CAS  PubMed  Google Scholar 

  42. Lee YI, Lim Y-S, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: a retrospective cohort study. J Gastroenterol Hepatol. 2012;27(1):91–5.

    Article  CAS  PubMed  Google Scholar 

  43. Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung S-H, et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther. 2017;45(2):345–53.

    Article  CAS  PubMed  Google Scholar 

  44. Kurra S, Fink DA, Siris ES. Osteoporosis-associated fracture and diabetes. Endocrinol Metab Clin N Am. 2014;43(1):233–43.

    Article  Google Scholar 

  45. Armstrong MJ, Adams LA, Canbay A, Syn W-K. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology. 2014;59(3):1174–97.

    Article  CAS  PubMed  Google Scholar 

  46. Chen H-J, Yang H-Y, Hsueh K-C, Shen C-C, Chen R-Y, Yu H-C, et al. Increased risk of osteoporosis in patients with nonalcoholic fatty liver disease. Medicine (Baltimore). 2018;97(42):e12835.

    Article  Google Scholar 

  47. Moon S-S, Lee Y-S, Kim SW. Association of nonalcoholic fatty liver disease with low bone mass in postmenopausal women. Endocrine. 2012;42(2):423–9.

    Article  CAS  PubMed  Google Scholar 

  48. Sun Y, Dai W, Liang Y, Yang P, Yang Q, Liang M, et al. Relationship between nonalcoholic fatty liver disease and bone mineral density in adolescents with obesity: a meta-analysis. Diabetes Metab Syndr Obes Targets Ther. 2019;12:199–207.

    Article  CAS  Google Scholar 

  49. Upala S, Jaruvongvanich V, Wijarnpreecha K, Sanguankeo A. Nonalcoholic fatty liver disease and osteoporosis: a systematic review and meta-analysis. J Bone Miner Metab. 2017;35(6):685–93.

    Article  CAS  PubMed  Google Scholar 

  50. Kotronen A, Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol. 2008;28(1):27–38.

    Article  CAS  PubMed  Google Scholar 

  51. Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis. 2015;47(3):181–90.

    Article  PubMed  Google Scholar 

  52. Park SK, Seo MH, Shin HC, Ryoo J-H. Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57(4):1378–83.

    Article  CAS  PubMed  Google Scholar 

  53. Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care. 2015;38(9):1673–9.

    Article  CAS  PubMed  Google Scholar 

  54. Björkström K, Stål P, Hultcrantz R, Hagström H. Histologic scores for fat and fibrosis associate with development of type 2 diabetes in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2017;15(9):1461–8.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unidad de Aparato Digestivo, Hospital Universitario Virgen del Rocio, Sevilla, Spain

    Yolanda Sanchez-Torrijos & Javier Ampuero

  2. Instituto de Biomedicina de Sevilla, Sevilla, Spain

    Javier Ampuero

  3. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain

    Javier Ampuero

  4. Universidad de Sevilla, Sevilla, Spain

    Javier Ampuero

Authors
  1. Yolanda Sanchez-Torrijos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Javier Ampuero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javier Ampuero .

Editor information

Editors and Affiliations

  1. UCM Digestive Diseases, Virgen del Rocio University Hospital, Sevilla, Spain

    Manuel Romero-Gomez

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Sanchez-Torrijos, Y., Ampuero, J. (2020). The Spectrum of NAFLD: From the Organ to the System. In: Romero-Gomez, M. (eds) NAFLD and NASH. Springer, Cham. https://doi.org/10.1007/978-3-030-37173-9_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-37173-9_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-37172-2

  • Online ISBN: 978-3-030-37173-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation